Video Guide
Catalyst Database
Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.
Ticker
Drug | Disease (links)
Stage (next event)
Catalyst Date
CRVS
Phase 1
Soquelitinib (CPI-818) (ITK inhibitor)
Atopic dermatitis
Q2 2025
4/9/24- Ph1 trial initiated with initial clinical data in Q4 2024. Final data in early 2025. 11/12/24- Ph1 interim data in December 2024. 12/18/24- Lowest dose cohorts showed a favorable safety & efficacy profile. 1/13/25- Announced data from Cohort 2, full results in Q2 2025.
Data readout
KROS
Phase 2
KER-012 (cibotercept)
Pulmonary arterial hypertension and cardiovascular disorders
Q2 2025
TROPOS trial. 07/2023- Ph2 trial cleared. Presentation at PVRI '24 on Feb 2, 2024. 9/3/24- Closed screening, complete enrollment by end of Sep. 12/12/24- halted dosing in the 3.0 & 4.5 mg/kg treatment arms. 1/15/25- Halted dosing in all treatment arms. Patients to be monitored through the end-of-trial visits. Topline data from all treatment arms expected in Q2 2025.
Data readout
VSTM
PDUFA
Avutometinib (VS-6766) +/- Defactinib
recurrent KRAS mutant LGSOC (Low-Grade Serous Ovarian Cancer)
June 30, 2025
RAMP 201 & RAMP 301 studies. 5/24/24- Initiated rolling NDA submission. 10/17/24 Present mature dataset (RAMP 201) at IGCS '24. 10/31/24- Completed rolling NDA submission. 12/30/24- FDA accepted NDA under priority review with PDUFA target action date June 30, 2025. 2/20/25- Data at SGO '25 on March 14-17, 2025.
Approval decision
JAGX
Phase 2
Crofelemer powder
Microvillus Inclusion Disease (MVID) & SBS
H1 2025
8/8/23- IND accepted, proceed w/ Ph2. 11/01/23- Received US patent. 5/9/24- Submits CTA for Ph2 study in Italy and Germany. 12/18/24- Ph2 initiated. 1/22/25 - First patient dosed in investigator-initiated trial in UAE, PoC data in H1 2025.
Data Readout
Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20
